Abstract
Adrenergic receptor signaling and heart failure are inextricably linked. Beta-adrenergic receptors (β-ARs) serve not only as physiological modulators of heart rate and contractility, they are also primary therapeutic targets of individuals with heart failure as well as many other cardiovascular disorders. In light of these relationships, this short review will focus on the basic pharmacology distinguishing adrenergic receptor subtypes; on receptor subtype selective signaling; the molecular basis of β-AR gene expression; and, delve briefly into genetic variation of β-ARs that represents a potential basis of differential natural history of heart failure progression and that may serve as an underlying basis for therapeutic response.
Keywords: Adrenergic receptors, signaling, gene regulation, genetic variation, heart failure
Current Signal Transduction Therapy
Title:Beta-adrenergic Signaling: Complexities and Therapeutic Relevance to Heart Failure
Volume: 7 Issue: 2
Author(s): J. David Port
Affiliation:
Keywords: Adrenergic receptors, signaling, gene regulation, genetic variation, heart failure
Abstract: Adrenergic receptor signaling and heart failure are inextricably linked. Beta-adrenergic receptors (β-ARs) serve not only as physiological modulators of heart rate and contractility, they are also primary therapeutic targets of individuals with heart failure as well as many other cardiovascular disorders. In light of these relationships, this short review will focus on the basic pharmacology distinguishing adrenergic receptor subtypes; on receptor subtype selective signaling; the molecular basis of β-AR gene expression; and, delve briefly into genetic variation of β-ARs that represents a potential basis of differential natural history of heart failure progression and that may serve as an underlying basis for therapeutic response.
Export Options
About this article
Cite this article as:
David Port J., Beta-adrenergic Signaling: Complexities and Therapeutic Relevance to Heart Failure, Current Signal Transduction Therapy 2012; 7 (2) . https://dx.doi.org/10.2174/157436212800376645
DOI https://dx.doi.org/10.2174/157436212800376645 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer
Current Medicinal Chemistry Economic Evaluation in Paediatric Practice: Examples from Cardiac Critical Care
Current Pediatric Reviews Regulation of the Endoplasmic Reticulum Ca2+-Store in Cancer
Anti-Cancer Agents in Medicinal Chemistry Mechanochemical Approaches to Pharmaceutical Cocrystal Formation and Stability Analysis
Current Pharmaceutical Design Regulation of G-Protein-Coupled Receptor Signalling by the Scaffolding Proteins Spinophilin/Neurabin 2 and Neurabin 1
Current Chemical Biology Study on the Effect of HPMC on Compression Coated Floating Pulsatile Delivery of Bisoprolol
Current Drug Therapy Immunity Modulators, Repurposed Drugs and Candidate Vaccines for COVID-19: A Review
Coronaviruses Ezetimibe and Reactive Oxygen Species
Current Vascular Pharmacology Use of Deoxyribozymes for Gene Knockdown
Medicinal Chemistry Reviews - Online (Discontinued) Epidemiology of Hypertension and Diabetes Mellitus in Latin America
Current Hypertension Reviews Improvement in Hypertension Management with Pharmacological and Non- Pharmacological Approaches: Current Perspectives
Current Pharmaceutical Design Antithrombotic Treatment after Atrial Fibrillation Ablation
Current Pharmaceutical Design Targeting Cytotoxic Conjugates of Somatostatin, Luteinizing Hormone- Releasing Hormone and Bombesin to Cancers Expressing Their Receptors: A “Smarter” Chemotherapy
Current Pharmaceutical Design Therapeutic Management of COVID-19 Patients: Clinical Manifestation and Limitations
Current Pharmaceutical Design Application of Decoy Oligonucleotides as Novel Therapeutic Strategy: A Contemporary Overview
Current Drug Discovery Technologies Chondromodulin-I and Tenomodulin: The Negative Control of Angiogenesis in Connective Tissue
Current Pharmaceutical Design Will Global Transcriptome Analysis Allow the Detection of Novel Prognostic Markers in Coronary Artery Disease and Heart Failure?
Current Genomics Perioperative Considerations in Rheumatoid Arthritis Patients
Current Rheumatology Reviews Novel Targets for Cardiac Antiarrhythmic Drug Development
Current Pharmaceutical Design Immunoregulatory Impact of Food Antioxidants
Current Pharmaceutical Design